Market Research Report
Europe Atopic Dermatitis Drugs Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||626307|
|Published||Content info||72 Pages
Delivery time: 1-2 business days
|Europe Atopic Dermatitis Drugs Market Forecast 2019-2027|
|Published: October 8, 2018||Content info: 72 Pages||
Experts have estimated that a high number of people belonging to the European population suffer from conditions such as conjunctivitis, skin allergies and food allergies. The market for atopic dermatitis drugs in Europe is, therefore expected to showcase a CAGR of 3.30% over the forecast period of 2019-2027.
Researchers have suggested that with the growing prices of the latest medications and increasing number of patients, the dependence on these medicines and drugs to treat symptoms is expected to increase. One of the fastest growing markets for atopic dermatitis drugs in the European market is Russia. According to forecasts, the country is expected to have the highest CAGR by 2027. The most probable reason for this might be poor hygienic conditions and heavy industrialization in the area.
Leading market players include Aqua Pharmaceuticals (An Almirall Company), Allergan Plc, Astellas Pharma Inc., Biofrontera Ag, Bayer Ag, Bristol-Myers Squibb, Encore Dermatology, Stiefel Laboratories, Inc, Galderma Sa, Meda Pharmaceuticals (Mylan N.V.), Leo Pharma,Novartis Ag, Regeneron Pharmaceuticals, Pfizer, Valent Pharmaceutical Inc and Sanofi Sa.